EN DE
Watch Sanigen Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sanigen Co. Ltd (188260) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Sanigen Co. Ltd stock KRW 1,763, price KRW 1,870, that is 5.7% below the price, quality 40 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

SC Sanigen Co. Ltd logo Thin data Nov 10, 2026

Sanigen Co. Ltd

188260 · KQ
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value 1,763 KRW · Fairly valued
Quality 40/100
Moderate debt
Weak Growth (revenue 3y −16.9 %/yr in KRW)
Loss-making · -27.4% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Sanigen Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

9,450 KRW 1,484 KRW Fair Value 1,763 KRW Nov 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

36‑month range 1,484 KRW – 9,450 KRW · fair‑value band 1,322 KRW – 2,203 KRW · the 1,870 KRW price screens above the 1,763 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Sanigen Co. in your weekly email

Every Wednesday you see whether Sanigen Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sanigen Co. Ltd, a food sanitation and safety specialist, develops and services solutions for safe food manufacturing, distribution, and sales in Korea and internationally.

Show moreShow less

The company offers PCR detection and nucleic acid extraction kits; bag, diluent, beam template, macroswab, and squeeze products; pathogen detection NGS panel kits; and hand sanitizers, vomit clean up kits, and pure systems.

It also provides Microbial, physicochemical analysis, and food sanitation/lab services. Sanigen Co. Ltd was founded in 2005 and is headquartered in Anyang-si, South Korea.

Stock analysis

Sanigen Co. Ltd (188260) currently trades at 1,870 KRW, while our estimate is 1,763 KRW, so the stock looks roughly fairly valued today (gap 6.1%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,322 KRW (bear) to 2,203 KRW (bull), the price of 1,870 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Sanigen Co. Ltd reported revenue of 15.4B KRW in FY2025 versus 25.2B KRW in FY2021, a compound −11.7%/yr. Reported net income was −5.8B KRW in FY2025.

Key figures

Market cap 25.1B KRW (≈ $18.8M) Micro · P/S ratio 1.85 · EPS (TTM) −283.16 KRW · Net margin −37.9% · Return on equity −39.3% · Return on assets (EBIT) −29.2% (5-year average) · Operating margin −10.6% · Revenue (TTM) 14.2B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −6%, 188260 screens cheaper than that median.

Fair Value

Bear 1,322 KRW Fair Value 1,763 KRW Bull 2,203 KRW
Price 1,870 KRW · Downside -5.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 38
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 32
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 30
Distance to the 52-week high, does not count
New shares 71
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−36.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−11.4% (2021) → −28.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 188260, get fair value alerts →

Compare Sanigen Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Above median
Fair Value upside −5.7% · Top 25%
Profitability
Return on assets −57.6% · Bottom 25%
Net margin (12 months) −27.4% · Below median
Operating margin (12 months) −10.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) −5.8% · Below median
Balance sheet
Debt / equity 0.69× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 10.12× · Priciest 25%
P/S (12 months) 1.76× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)26 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)66 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 188260
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 188260
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 188260
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 188260
argenx SE ARGX $971.55 $908.40 −7% vs 188260
CSL Limited CSL A$201.68 A$181.40 −10% vs 188260
Moderna, Inc MRNA $250.83 $158.70 −37% vs 188260
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 188260
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 188260
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 188260

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sanigen Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sanigen Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/188260

Frequently asked questions

Is Sanigen Co. Ltd (188260) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 1,763 KRW versus a price of 1,870 KRW, about 6% lower (fairly valued).
What is the fair value of 188260?
Our estimate for Sanigen Co. Ltd is 1,763 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 1,870 KRW.
What is the quality score of 188260?
Sanigen Co. Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sanigen Co. Ltd (188260)?
Our calculated price target is the estimate of 1,763 KRW (as of Nov 10, 2026). Cautious scenario 1,322 KRW, optimistic scenario 2,203 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sanigen Co. Ltd stock forecast for 2026?
Our estimate puts fair value at 1,763 KRW, about 6% lower versus a price of 1,870 KRW (fairly valued). Cautious scenario 1,322 KRW, optimistic scenario 2,203 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Sanigen Co. Ltd (188260)?
Sanigen Co. Ltd reported trailing-twelve-month revenue of about 14.2B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Sanigen Co. Ltd (188260)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sanigen Co. Ltd it is 1,763 KRW per share (as of Nov 10, 2026), against a price of 1,870 KRW.
Is Sanigen Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 188260 trades above its calculated fair value: price 1,870 KRW, fair value 1,763 KRW, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 188260?
No. The price is what the market pays today (1,870 KRW); the fair value is what the company's own numbers justify (1,763 KRW). For Sanigen Co. Ltd the two are 107.31 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Sanigen Co. Ltd worth?
The market values Sanigen Co. Ltd at about 25.1B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 1,870 KRW; our models calculate a fair value of 1,763 KRW per share.
What do the bullish and bearish scenarios say about 188260?
Our models span a range for Sanigen Co. Ltd: cautious scenario 1,322 KRW, base 1,763 KRW, optimistic 2,203 KRW per share (as of Nov 10, 2026, price 1,870 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sanigen Co. Ltd (188260)?
Balance-sheet figures for Sanigen Co. Ltd (as of Nov 10, 2026): return on equity −39.3%, debt of 0.69 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 188260 from its 52-week high?
Sanigen Co. Ltd trades at 1,870 KRW, about 17% below its 52-week high of 2,250 KRW and 26% above the low of 1,484 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 1,763 KRW is for.
Which stocks are comparable to Sanigen Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sanigen Co. Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 1,870 KRW, calculated fair value 1,763 KRW (−6%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Sanigen Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sanigen Co. Ltd (188260)?
The closing price on Nov 10, 2026 was 1,870 KRW. Our estimate is 1,763 KRW, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sanigen Co. Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sanigen Co. Ltd

How large is the market capitalisation of Sanigen Co. Ltd (188260)?
The market capitalisation of Sanigen Co. Ltd is 25.1B KRW (≈ $18.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sanigen Co. Ltd (188260)?
The price-to-sales ratio of Sanigen Co. Ltd is 1.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sanigen Co. Ltd (188260)?
Earnings per share at Sanigen Co. Ltd are −283.16 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sanigen Co. Ltd (188260)?
The net margin of Sanigen Co. Ltd is −37.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sanigen Co. Ltd (188260)?
The return on equity (ROE) of Sanigen Co. Ltd is −39.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sanigen Co. Ltd (188260)?
On an EBIT basis the return on assets of Sanigen Co. Ltd is −29.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sanigen Co. Ltd (188260)?
The operating margin of Sanigen Co. Ltd is −10.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sanigen Co. Ltd (188260)?
Revenue at Sanigen Co. Ltd is growing −5.8% versus a year earlier (3y avg −16.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sanigen Co. Ltd (188260) generate?
The free cash flow of Sanigen Co. Ltd is −4.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sanigen Co. Ltd (188260) carry?
The net debt of Sanigen Co. Ltd is 882M KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sanigen Co. Ltd in the live analysis

One click puts Sanigen Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.